Regeneron makes second bid for blood cancer therapy approval
The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Managed Healthcare Executive4d
FDA Accepts BLA Resubmission for Follicular Lymphoma Drug, Odronextamab
The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...
The Pharma Letter4d
Odronextamab BLA resubmission accepted for FDA review
The US Food and Drug Administration (FDA) has accepted for review Regeneron Pharmaceuticals’ resubmission of the Biologics ...
Regeneron Pharmaceuticals, Inc.: Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...
STERIS plc (STE) Slid on Cautious Health Care Sentiment
The London Company, an investment management company, released “The London Company Mid Cap Strategy” fourth quarter 2024 ...
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
healthandpharma5d
Odronextamab Gains FDA Review for Hard-to-Treat Relapsed/Refractory Follicular Lymphoma
Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...
JD Supra5d
Biologics and Biosimilars Landscape 2024: IP, Policy, and Market Developments
Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...
The Pharma Letter5d
Regeneron’s DB-OTO demonstrates dramatic hearing improvement
US biotech Regeneron Pharmaceuticals says that its investigational gene therapy DB-OTO showed clinically-meaningful hearing ...
Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...
American Association of Individual Investors9d
Which Is a Better Investment, AbbVie Inc. or Regeneron Pharmaceuticals, Inc. Stock?
Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...
Seeking Alpha14d
Why Regeneron's Price May Soon Break Out
Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...